Morning Report | Hormuz squeeze keeps energy risk premium high
$IBM $1B CHIPS quantum LOI · $MSFT Maia chips eyed for Azure · $SPOT paid AI voice tools pitch · $IPO SpaceX filing stirs IPO appetite · $GS lead-bank focus on roadshow
Market Pulse
U.S.-Iran War
2 events
Hormuz traffic near-halted keeps crude risk premium elevated as U.S.-Iran talks show progress but deadlock persists over enriched uranium and shipping controls.
Last 24 hours
Oil rebounded in early Asia with Brent Jul up about 1.9% to ~$104.52 and WTI Jun up about 1.5% to ~$97.81 after reports Iran would not send enriched uranium abroad.
Secretary of State Rubio cited “good signs” toward a deal but said it would be unfeasible if Iran imposes Hormuz control measures or tolls; shipping traffic is described as virtually halted.
Market reaction
Crude bounced after three down sessions: Brent Jul +~1.9% to ~$104.52 and WTI Jun +~1.5% to ~$97.81, underscoring headline-driven volatility tied to negotiations and Hormuz disruptions.
Our view
An elevated, volatile crude backdrop while Hormuz disruption persists and nuclear terms remain unresolved. The key monitor is any verified reopening of Hormuz shipping alongside an agreement on enriched uranium terms sufficient to reduce the geopolitical premium.
What could change our view
Durable reopening of Strait of Hormuz with credible deal compresses the risk premium.
Renewed military action or tighter blockades further disrupt flows and spikes crude.
Tickers: $CL=F
Macro & Policy Digest
IEA flags a July/August oil “red zone” if the Strait of Hormuz stays constrained, with stock draws and summer demand amplifying supply shocks.
Last 24 hours
IEA’s Fatih Birol warned markets could hit a “red zone” in Jul/Aug without a full Hormuz reopening and Middle East supply/refining return; March saw a coordinated 400m-bbl strategic release with more possible.
Market reaction
Brent rose 1.9% to $106.92/bbl and WTI gained 2.4% to $100.59/bbl, with both cited as roughly +45% since the Iran war began.
Our view
Crude stays bid with an elevated geopolitical risk premium into peak summer demand as long as Hormuz remains constrained, while coordinated strategic releases likely limit the tails rather than reset the level. The next inflection is any credible signal on Hormuz flow normalization or fresh reserve-release coordination.
What could change our view
Strait of Hormuz reopens fully and Middle East supply/refining normalizes quickly.
Larger-than-expected coordinated strategic releases materially ease near-term balances.
Tickers: $CL=F
NIST issues letters of intent for a $2B CHIPS quantum package with minority equity stakes, highlighted by $1B for IBM.
Last 24 hours
NIST outlined ~$2.0B of quantum-related grants to nine firms with minority, non-controlling U.S. equity stakes; IBM is slated for $1.0B tied to its planned “Anderon” Albany 300mm quantum wafer foundry, plus a $1.0B IBM match.
Our view
Treat the announcement as a policy tailwind for the listed beneficiaries, with IBM the clearest near-term focal point given the proposed $1B award and matching investment plan. The key monitor is conversion of letters of intent into finalized award agreements, including any conditions attached to the equity stakes.
What could change our view
Letters of intent fail to convert into final awards or amounts are reduced.
Final terms of minority equity stakes add restrictive conditions or dilute economics.
Tickers: $IBM
Company Events
AI monetization and infrastructure plays broaden as Spotify pitches paid AI voice tools and Microsoft explores externalizing Maia chips via Azure.
Last 24 hours
At its first investor day since 2022, Spotify set 2030 targets of 1B subscribers and $100B revenue, guiding mid-teens revenue CAGR and 35%–40% gross margin.
Microsoft is in talks to supply its in-house Maia AI accelerator chips to Anthropic through Azure, which would be the first meaningful external availability, though no agreement is finalized.
Our view
The near-term readthrough is continued AI-driven pricing and product differentiation, favoring platforms that can create incremental ARPU or lower inference cost per workload. Next to watch is whether Spotify’s paid AI add-on launches with broad opt-in participation and whether Microsoft converts talks into an announced Azure Maia offering.
What could change our view
AI licensing frameworks fail to scale, prompting renewed rights-holder disputes.
Microsoft–Anthropic Maia discussions stall, limiting Azure custom silicon differentiation.
Tickers: $SPOT, $MSFT
SpaceX’s Nasdaq IPO filing sets up a June roadshow and outsized retail allocation, putting IPO sentiment and lead banks in focus.
Last 24 hours
SpaceX filed an S-1 to list on Nasdaq as SPCX, with CNBC citing a June 8 roadshow and ~June 12 pricing; reports flag ~$1.75T valuation and up to $75B raise plus retail access via HOOD/Fidelity/SCHW.
FT reports Goldman won the lead-left mandate for the SpaceX IPO, while Morgan Stanley is named as stabilisation agent in the filing, an unusually explicit role split for post-IPO aftermarket support.
Our view
The filing catalyzes near-term IPO/ECM attention with incremental upside to deal-lead franchises and retail distribution platforms tied to allocations. Monitor final valuation/raise size and disclosed retail tranche ahead of the June roadshow/pricing as key determinants of broader risk appetite spillover.
What could change our view
Roadshow or pricing slips materially from the cited June window.
Retail allocation or valuation guidance is scaled back, dampening demand.
Tickers: $IPO, $GS
Autonomy split-screen: Tesla brings supervised FSD to China while Waymo pauses robotaxi freeway routes to push safety software updates.
Last 24 hours
Tesla said Full Self-Driving (Supervised) is now available in China as part of a 10-market rollout, with its China site listing an “intelligent assisted driving” one-time fee of 64,000 yuan and near-term feature updates.
Waymo temporarily halted robotaxi freeway operations in several U.S. markets to integrate updates after construction-zone issues, while keeping surface-street service active amid an NHTSA recall covering 3,791 vehicles running its 5th- and 6th-generation ADS.
Our view
Autonomy remains a push-pull between monetization expansion and operational safety constraints, with Tesla’s China availability supporting attach-rate optionality while Waymo’s freeway pause reinforces execution risk. Next watchpoints are Tesla’s pace of feature updates in China and Waymo’s timing to resume freeway routes alongside a finalized recall remedy.
What could change our view
China regulators constrain Tesla assisted-driving feature updates or commercialization terms.
Waymo’s final remedy slips, extending freeway suspension or widening ODD restrictions.
Tickers: $TSLA, $GOOGL
M&A tape stays idiosyncratic as Estée Lauder scraps Puig talks while IMAX tests sale interest, both names gap higher on reduced uncertainty or takeout optionality.
Last 24 hours
Estée Lauder ended exploratory business-combination discussions with Spain’s Puig and reaffirmed its “Beauty Reimagined” turnaround, including a $1.2B–$1.6B restructuring plan with up to ~10,000 positions targeted.
IMAX is exploring a potential sale; a CNBC source said preliminary buyer talks occurred via intermediaries, with no official pitches, buyer, price, structure, timetable, LOI, or definitive agreement disclosed.
Market reaction
EL rose ~9.6% premarket/after-hours after terminating the Puig talks while Puig fell nearly ~14% in Europe; IMAX gained about ~10% in extended trading on the sale-exploration report.
Our view
Expect deal speculation to remain selective rather than broad-based, with markets rewarding clarity on standalone execution (EL) and paying for strategic-option value where a process could formalize (IMAX). The key monitor is whether IMAX moves from market-testing to a launched process and whether EL’s turnaround milestones keep replacing deal premium.
What could change our view
IMAX talks stall or leak unfavorable terms, reversing the takeout premium.
EL execution slips or costs rise, reviving pressure for a larger combination.
Tickers: $EL, $IMAX
Lilly’s retatrutide Phase 3 obesity data shows outsized weight loss durability, reinforcing GLP-1 leadership stakes and setting up a regulatory filing path.
Last 24 hours
Lilly reported pivotal Phase 3 retatrutide results in ~2,500 obesity patients: highest dose drove 28.3% mean weight loss at 80 weeks vs 2.2% placebo, with ~45% achieving ≥30%; extension cohort (BMI≥35) showed 30.3% loss at 104 weeks, while discontinuations were 11.3% on highest dose and GI events were common.
Our view
The readout strengthens expectations that retatrutide can be a best-in-class obesity asset, supporting Lilly’s competitive positioning within GLP-1 and adjacent healthcare exposures. Next monitor is the approval-filing timeline and whether tolerability/discontinuation at higher doses constrains the label and real-world uptake.
What could change our view
Higher-dose discontinuations and GI side effects force a narrower label or lower dosing.
Regulatory filing or review delays push commercialization timing and shift competitive dynamics.
Tickers: $LLY
AVB and EQR strike largest-ever all-stock REIT merger, creating a ~$52B apartment giant that could reshape listed real estate index weights.
Last 24 hours
AvalonBay and Equity Residential announced an all-stock combination implying ~$52B market cap and ~$69B enterprise value, with Benjamin Schall to lead and Mark Parrell retiring at close, pending shareholder approvals.
Our view
The deal proceeds as announced, favoring AVB/EQR relative stability and putting apartment REIT peers and real-estate ETFs on watch for index and consolidation knock-ons. Key monitor is the proxy/vote timeline and any unexpected political or regulatory scrutiny beyond PR around housing affordability.
What could change our view
Shareholder votes or closing mechanics slip, extending uncertainty around the transaction.
Political scrutiny escalates into formal intervention despite expectations of no antitrust approvals.
Tickers: $AVB
Walmart EPS guidance cut flags fuel-driven pressure on budget consumers as tax-refund support fades into Q2.
Last 24 hours
Walmart lowered FY adjusted EPS to $2.75–$2.85 (vs $2.91 consensus) and current-quarter to $0.72–$0.74 (vs $0.75), citing higher gasoline costs and fading tax-refund tailwinds.
Market reaction
WMT shares fell roughly 7%–8% after the outlook cut, refocusing attention on U.S. consumer resilience.
Our view
Treat the guidance cut as a near-term margin headwind rather than a demand collapse, with sales still guided to grow and higher-margin digital/ads trends providing partial offset. Next check is whether fuel costs persist into Q2 and further compress basket size/behavior at the pump.
What could change our view
Fuel prices stay elevated, making the expected Q2 fuel headwind larger.
Consumer strain broadens beyond fuel, undermining sales growth assumptions.
Tickers: $WMT
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read Evening Insights.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.